Abstract
Menorrhagia is one of the most important and frequent complications in women with congenital von Willebrand disease (vWD). Three cases of menorrhagia with vWD (type 1; 1 case, type 2A; 2 cases) were successfully treated with tranexamic acid at dose of 3 grams daily in four divided doses for the first 5 days of the menstrual cycle. All patients had severe menorrhagia lasted for more than 10 days with iron deficiency anemia of hemoglobin levels of 6.5–8.4 g/dl. Common dosage of tranexamic acid of 1 gram daily in 4 divided doses on days 1–5 of their menstrual cycles did not correct their menorrhagia. The treatment was then changed to the daily dose of 3 grams in 4 divided doses on days 1–5 of their menstrual cycles. Thereafter, their menorrhagia became well-controlled with improvement of their anemia up to hemoglobin of 11.5–12.4 g/dl. High dose of tranexamic acid has been administered safely in all patients for 3–5 years without significant complications. Oral high-dose administration of tranexamic acid is very convenient and useful for treatment of menorrhagia in the patients with vWD.
Similar content being viewed by others
References
Ruggeri ZM. Cell adhesion in vascular biology. von Wille-brand factor. J Clin Invest 1997;99:559–566.
Federici AB. Diagnosis of von Willebrand disease. Haemophilia 1998;4:654–660.
Lee CA. Women and inherited bleeding disorders: menstrual issues. Semin Hematol 1999;36:21–27.
Hoylearts M, Lijnen HR, Collen D. Studies on the mechanism of the antifibrinolytic action of tranexamic acid. Biochim Biophys Acta 1981;673:75–85.
Thorsen S. Differences in the binding to fibrin of native plasminogen and plasminogen modified by proteolytic degradation. Influence of omega-aminocarboxylic acids. Biochim Biophys Acta 1975;393:55–65.
Mezzano D, Panes O, Munoz B, et al. Tranexamic acid inhibits fibrinolysis, shortens bleeding time and improves platelet function in patients with chronic failure. Thromb Haemost 1999;82:1250–1254.
Ong YL, Hull DR, Mayne EE. Menorrhagia in von Wille-brand disease successfully treated with single daily dose tranexamic acid. Haemophilia 1998;4:63–65.
Gleeson NC, Buggy F, Sheppard BL, Bonnar J. The effect of tranexamic acid on measured menstrual loss and endometrial fibrinolytic enzymes in dysfunctional uterine bleeding. Acta Obstet Gynecol Scand 1994;73:274–277.
Hallberg L, Hogdahl AM, Nilsson L, Rybo G. Menstrual blood loss-a population study. Acta Obstet Gynecol Scand 1966;45:320–351.
Mannucci PM. Treatment of von Willebrand disease. Haemophilia 1998;4:661–664.
Federici AB, Mannucci PM, Optimizing therapy with factor VIII/von Willebrand factor concentrates in von Willebrand disease. Haemophilia 1998;4:7–10.
Bonnar J, Sheppard BL, Dockeray CJ, Coagulation/the haemostatic system and dysfunctional uterine bleeding. Res Clin Forum 1983;5:27–36.
Andersch B, Milsom I, Rybo G. An objective evaluation of flubiprofen and tranexamic acid in the treatment of idiopathic menorrhagia. Acta Obstet Gynecol Scand 1988;67:645–648.
Nilsson L, Rybo G. Treatment of menorrhagia with an antifibrinolytic agent, tranexamic acid (AMCA). Acta Obstet Gynecol Scand 1967;46:572–580.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Mohri, H. High Dose of Tranexamic Acid for Treatment of Severe Menorrhagia in Patients with von Willebrand Disease. J Thromb Thrombolysis 14, 255–257 (2002). https://doi.org/10.1023/A:1025013213192
Issue Date:
DOI: https://doi.org/10.1023/A:1025013213192